PE
FOLD

Point72 Europe’s Amicus Therapeutics FOLD Stock Holding History

Point72 Europe’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$46.3K Buy
+5,877
New +$41.8K ﹤0.01% 377

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Point72 Europe's FOLD Position: Q3 2025 in Review

Point72 Europe opened a new position in Amicus Therapeutics (FOLD) in Q3 2025: 5,877 shares worth $46.3K. The stake represents ﹤0.01% of the portfolio and ranks #377 among its holdings.

287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Point72 Europe held 5,877 shares of Amicus Therapeutics worth $46.3K as of Q3 2025.
  • Amicus Therapeutics was a new Point72 Europe position in Q3 2025.
  • Amicus Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #377 holding.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.